Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma

Oncotarget

Volumn 6, Issue 14, 2015, Pages 12340-12356

  Jiang, Xiufeng ^a,b   Feng, Kang ^b   Zhang, Ye ^a   Li, Zengyao ^b   Zhou, Fan ^b   Dou, Huiqiang ^a   Wang, Tong ^a,b  

^a WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

c Met inhibitor; Combination; Hepatocellular carcinoma; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; DE 605; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; SCATTER FACTOR RECEPTOR; SORAFENIB; UNCLASSIFIED DRUG; (4-(4-(6-AMINO-5-(BENZO(D)OXAZOL-2-YL)PYRIDIN-3-YL)-1H-PYRAZOL-1-YL)PIPERIDIN-1-YL)ETHANONE; AMINOPYRIDINE DERIVATIVE; BENZOXAZOLE DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; MTT ASSAY; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUNEL ASSAY; WESTERN BLOTTING;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZOXAZOLES; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LIVER NEOPLASMS; MICE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84931297386     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3656     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. El-Serag HB and Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132:2557-2576.
3. Llovet JM, Burroughs A and Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362:1907-1917.
4. Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010; 80:550-560.
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol. 2009; 10:25-34.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359:378-390.
7. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008; 7(10):3129-3140.
8. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M and Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006; 66:11851-11858.
9. Rosmorduc O and Desbois-Mouthon C. Targeting STAT3 in hepatocellular carcinoma: sorafenib again. J Hepatol. 2011; 55:957-959.
10. Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ and Chen KF. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol. 2011; 55:1041-1048.
11. Borowiak M, Garratt AN, Wustefeld T, Strehle M, Trautwein C and Birchmeier C. Met provides essential signals for liver regeneration. Proc Natl Acad Sci USA. 2004; 101:10608-10613.
12. Sakata H, Takayama H, Sharp R, Rubin JS, Merlino G and LaRochelle WJ. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ. 1996; 7:1513-1523.
13. Jung KH, Park BH and Hong SS. Progress in cancer therapy targeting c-Met signaling pathway. Arch Pharm Res. 2012; 35(4):595-604.
14. You H, Ding W, Dang H, Jiang Y and Rountree CB. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology. 2011; 54:879-889.
15. Eder JP, Vande Woude GF, Boerner SA and LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15:2207-2214.
16. Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R and Bishop JM. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci USA. 2007; 104:14771-14776.
17. Wang R, Ferrell LD, Faouzi S, Maher JJ and Bishop JM. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol. 2001; 153:1023-1034.
18. Kiss A, Wang NJ, Xie JP and Thorgeirsson SS. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/cmet, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 1997; 3:1059-1066.
19. Lee SJ, Lee J, Sohn I, Mao M, Kai W, Park CK and Lim HY. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer research. 2013; 33:5179-5186.
20. Ljubimova JY, Petrovic LM, Wilson SE, Geller SA and Demetriou AA. Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 1997; 45:79-87.
21. Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, Zhao CH, Lin L, Brunetti AE, Fu YL, Wang J, Paradiso A and Xu JM. Expression and prognostic value of VEGFR-2, PDGFR-beta, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2013; 32:16.
22. Goyal L, Muzumdar MD and Zhu AX. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19:2310-2318.
23. Inagaki Y, Qi F, Gao J, Qu X, Hasegawa K, Sugawara Y, Tang W and Kokudo N. Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci Trends. 2011; 5:52-56.
24. Llovet JM and Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008; 48(4):1312-1327.
25. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A and Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget. 2012; 3:236-260.
26. Wang WQ, Liu L, Xu HX, Sun HC, Wu CT, Zhu XD, Zhang W, Xu J, Liu C, Long J, Ni QX, Tang ZY and Yu XJ. The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. Oncotarget. 2014; 5:3895-3906.
27. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS and Li CJ. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010; 9:1544-1553.
28. Hong SW, Jung KH, Park BH, Zheng HM, Lee HS, Choi MJ, Yun JI, Kang NS, Lee J and Hong SS. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer. Cancer letters. 2013; 33:74-82.
29. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M and Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24:4293-4300.
30. Villanueva A and Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011; 140:1410-1426.
31. Kudo M. Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol. 2012; 18:6005-6017.
32. Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4:915-925.
33. Patane S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, Vigna E, Naldini L, Baldini N, Ferracini R, Corso S, Giordano S, Comoglio PM and Di Renzo MF. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 2006; 66:4750-4757.
34. Wang JY, Del Valle L, Gordon J, Rubini M, Romano G, Croul S, Peruzzi F, Khalili K and Reiss K. Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas. Oncogene. 2001; 20:3857-3868.
35. Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A and Lancaster JM. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013; 29:2011-2018.
36. Yashiro M, Nishii T, Hasegawa T, Matsuzaki T, Morisaki T, Fukuoka T and Hirakawa K. A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma. Br J Cancer. 2013; 109:2619-2628.
37. Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Gradler U, Meyring M, Dorsch D, Jaehrling F, Pehl U, Stieber F, Schadt O and Blaukat A. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19:2941-2951.
38. Liu X, Newton RC and Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010; 16:37-45.
39. Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, Pan SL and Teng CM. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20:1274-1287.
40. Chen KF, Tai WT, Liu TH, Huang HP, Lin YC, Shiau CW, Li PK, Chen PJ and Cheng AL. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16:5189-5199.
41. Imura Y, Yasui H, Outani H, Wakamatsu T, Hamada K, Nakai T, Yamada S, Myoui A, Araki N, Ueda T, Itoh K, Yoshikawa H and Naka N. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma. Molecular cancer. 2014; 13:185.
42. Park BH, Jung KH, Yun SM, Hong SW, Ryu JW, Jung H, Ha JD, Lee J and Hong SS. KRC-327, a selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity. Cancer letters. 2013; 331:158-166.
43. Liu Y, Liu JH, Chai K, Tashiro S, Onodera S and Ikejima T. Inhibition of c-Met promoted apoptosis, autophagy and loss of the mitochondrial transmembrane potential in oridonininduced A549 lung cancer cells. The Journal of pharmacy and pharmacology. 2013; 65:1622-1642.
44. Liu Y, Yang Y, Ye YC, Shi QF, Chai K, Tashiro S, Onodera S and Ikejima T. Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells. Journal of pharmacological sciences. 2012; 118:423-432.
45. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD and Soo KC. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol. 2010; 52:79-87.
46. Morelli MP, Tentler JJ, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S, Arcaroli JJ, Serkova NJ, Hidalgo M, Ciardiello F and Eckhardt SG. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18:1051-1062.
47. Yu C, Dasmahapatra G, Dent P and Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia. 2005; 19:1579-1589.
48. Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, Friedman SL and Llovet JM. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol. 2012; 56:1343-1350.
49. Bladt F, Friese-Hamim M, Ihling C, Wilm C and Blaukat A. The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models. Cancers. 2014; 6:1736-1752.
50. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR and Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007; 408:297-315.
51. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58:621-681.
52. Sun HL, Tsai AC, Pan SL, Ding Q, Yamaguchi H, Lin CN, Hung MC and Teng CM. EPOX inhibits angiogenesis by degradation of Mcl-1 through ERK inactivation. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15:4904-4914.
53. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402-408.
54. Sun FX, Tohgo A, Bouvet M, Yagi S, Nassirpour R, Moossa AR and Hoffman RM. Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res. 2003; 63:80-85.
55. Prasad R, Vaid M and Katiyar SK. Grape proanthocyanidin inhibit pancreatic cancer cell growth in vitro and in vivo through induction of apoptosis and by targeting the PI3K/Akt pathway. PLoS One. 2012; 7:e43064.